
The METRO PLUS Trial: Metronomic Chemotherapy Added to Paclitaxel-Carboplatin in Advanced HNSCC
Can a $180-a-year regimen close the access gap in advanced head and neck cancer? In this episode we cover METRO PLUS (Kapoor et al., JCO Global Oncology 2026), a single-center, open-label, phase III trial from Varanasi t


























